Our Products

Bylvay is a once-daily non-systemic ileal bile acid transport (IBAT) inhibitor that blocks the action of IBAT, a protein in the intestine that transports bile acid from the intestines back to the liver. Excess bile acid is excreted, ultimately resulting in a decrease in serum bile acids that can form in the liver and cause cholestasis. Bylvay is approved for all types of progressive familial intrahepatic cholestasis (PFIC) in patients aged 3 months and older in the U.S. and in patients aged 6 months and older in the E.U. Bylvay is also approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS)  from 12 months of age in the U.S. and in children from 6 months of age in the E.U., where it is known as Kayfanda^®.

A tyrosine kinase inhibitor (TKI) used in the treatment of advanced kidney cancer (advanced renal cell carcinoma – aRCC) as monotherapy or in combination with nivolumab. It is also indicated in adults living with liver cancer (hepatocellular carcinoma) previously treated with the medicine sorafenib. In the E.U., it is also indicated for the treatment of adults with locally advanced or metastatic differentiated thyroid carcinoma (DTC), who are refractory or not eligible to radioactive iodine and who have progressed after prior systemic therapy.

A tyrosine kinase inhibitor (TKI) used to treat people with progressive, unresectable or locally advanced medullary thyroid cancer (MTC) or MTC that has spread to other parts of the body (metastatic MTC).

An analog of the natural gonadotropin-releasing hormone (GnRH), halting the production of sexual hormones. It is approved for the treatment of high-risk localized, locally advanced or metastatic prostate cancer, endometriosis, uterine fibroids and central precocious puberty (CPP). It is also approved as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor for women at high risk of recurrence of endocrine-responsive early-stage breast cancer. It is also used to induce ovulation for in vitro fertilization.

An acetylcholine release inhibitor and a neuromuscular blocking agent, Dysport contains a toxin produced by the bacterium Clostridium botulinum indicated for symptomatic treatment of focal spasticity of the upper and lower limbs in adults and children over two years old.

It is also indicated for adults for symptomatic treatment of:

• Spasmodic torticollis (cervical dystonia)
• Blepharospasm
• Hemifacial spasm
• Severe primary hyperhidrosis of the axillae

Also used for the temporary improvement in the appearance of moderate to severe glabellar and lateral canthal lines associated with procerus and corrugator muscle activity in adults under 65.